Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LTZ-232 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on LTZ-232, a putative bispecific antibody targeting EPCAM (Oct 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LTZ-232 | LTZ232|LTZ 232 | Limited information is currently available on LTZ-232, a putative bispecific antibody targeting EPCAM (Oct 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07878988 | Phase I | LTZ-232 | This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors | Recruiting | USA | 0 |